Introduction
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Uses
Brolucizumab is an anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Associated Conditions
Pharmacodynamics
Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which reduces proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. It has a long duration of action as it is given monthly. Patients should be counselled regarding the risk of endophthalmitis, retinal detachment, and arterial thromboembolic events following administration of this medication.
Mechanism of Action
Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.
Absorption
A 3mg dose of brolucizumab reaches a Cmax of 20.7ng/mL with a Tmax of 20.3h and an AUC of 2480ng*h/mL. A 6mg dose of brolucizumab reaches a Cmax of 77.6ng/mL with a Tmax of 17.4h and an AUC of 9169ng*h/mL.
Volume of Distribution
Data regarding the volume of distribution is not readily available.
Protein Binding
Monoclonal antibodies are generally not protein bound in serum.
Route of Elimination
Data regarding the route of elimination is not readily available. Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.
Half Life
The systemic half life of bolucizumab is 4.4±2.0 days. The elimination half life is 108h for a 3mg dose and 103h for a 6mg dose.
Clearance
Data regarding the clearance of brolucizumab is not readily available.
Toxicity
Data regarding the toxicity of brolucizumab is not readily available.
Food Interactions
No interactions found.
Dosage
Diabetic Macular Edema (DME): The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (approximately every 39-45 days) for the first five doses, followed by one dose of 6 mg (0.05 mL of 120 mg/mL solution) every 8-12 weeks.
Pediatric Use: The safety and efficacy of BEOVU in pediatric patients has not been established.
